Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient
Status:
Completed
Trial end date:
2020-05-30
Target enrollment:
Participant gender:
Summary
It has been identified that nonadherence to immunosuppressant regimen may cause long-term
graft failure and death in solid organ transplant recipients. Therefore, simplification of
the immunosuppression regimen by reducing daily dosing frequency may improve long-term
outcome. The investigators will examine pharmacokinetics and safety profiles of stable liver
transplant recipients receiving twice-daily TAC with EVR (BID) regimen and then being
converted to once-daily TAC with EVR (QD) regimen over a 6-month study period
post-conversion.